Comparative Pharmacology
Head-to-head clinical analysis: PYLORI CHEK BREATH TEST versus THYPINONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYLORI CHEK BREATH TEST versus THYPINONE.
PYLORI-CHEK BREATH TEST vs THYPINONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
THYPINONE is a synthetic thyrotropin-releasing hormone (TRH) analog that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary. It also has central nervous system effects, potentially modulating neurotransmitter release and exhibiting neuroprotective properties.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
Oral: 5 mg twice daily; intravenous: 2.5 mg bolus followed by 1 mg/hour continuous infusion.
None Documented
None Documented
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
Terminal half-life 8-12 hours; prolonged to 20-30 hours in severe hepatic impairment, requiring dose adjustment
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Renal (70% unchanged), biliary/fecal (25% as glucuronide metabolites), 5% other
Category C
Category C
Diagnostic Agent
Diagnostic Agent